Vulvovaginal atrophy: modern approaches to diagnostics and management

Authors

DOI:

https://doi.org/10.14739/2310-1210.2024.6.311942

Keywords:

vulvovaginal atrophy, genitourinary menopause syndrome, menopause, postmenopause, hypoestrogenism, diagnosis, treatment, photodynamic therapy

Abstract

The aim of the review is to analyze the latest data on the current state of diagnosis and management of a common benign vulvar and vaginal disease in postmenopausal women – atrophic vulvovaginitis.

The paper presents an analysis of national and foreign scientific publications on the diagnosis and management of vulvovaginal atrophy and also focuses on the modern nomenclature and terminology of this pathology. Vulvovaginal atrophy is a common and progressive condition affecting on average more than 50 % of postmenopausal women, and its development and severity depend mainly on the duration of hypoestrogenism. Such a hormonal imbalance with a gradually increasing estrogen deficiency leads to atrophic changes in the tissues of the female genital organs and thinning of the vaginal epithelium. Degenerative alterations are accompanied by inflammatory phenomena and disturbances in the vaginal microflora. Atrophic lesions in the genitourinary system induce urinary incontinence aggravation, dysuria, increased micturition frequency, and recurrent urinary tract infections.

Vulvovaginal atrophy is diagnosed based on appropriate clinical assessments as well as with the involvement of validated questionnaires. Differential diagnosis of the vulvovaginal atrophy should include all pathological conditions imitating the clinical symptoms and signs.

Experts of the International Society for the Study of Women’s Sexual Health and the North American Society of Menopause have proposed a new nomenclature, namely, the terms “vulvovaginal atrophy” and “atrophic vaginitis” have been supplanted by “genitourinary menopausal syndrome”.

First-line therapy for mild symptoms is non-hormonal vulvar and vaginal lubricants, vaginal moisturizers used on a regular basis. Hormonal therapy (both transdermal and oral) remains the most effective choice for the treatment of clinical manifestations, but contraindications to its use should be considered. In women with contraindications to systemic hormonal therapy, it is possible to prescribe estrogens in the form of vaginal suppositories or vaginal cream. 5-Aminolevulinic acid photodynamic therapy can be one of the promising methods in the treatment of this women’s clinical group.

Given the serious consequences of vulvovaginal atrophy for the patients’ health and quality of life, timely diagnosis of the disease in accordance with its specificity and possible complications is of primary importance for the successful treatment and management of this pathology.

Conclusions. Vulvovaginal atrophy has been shown to be a common disease, especially among women in the postmenopausal period, based on the analysis of national and foreign scientific publications. The pathogenesis of vulvovaginal atrophy is associated with hypoestrogeny which results in structural and functional abnormalities of the genital organs such as mucus thinning, loss of elasticity, changes in microbiota and increased pH. Given the new nomenclature and terminology, it is appropriate to use the term “genitourinary menopausal syndrome” (GMS or GUMS) in lieu of “vulvovaginal atrophy”.

Author Biographies

V. H. Siusiuka, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, DSc, Professor, Head of the Department of Obstetrics and Gynecology

N. V. Avramenko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Obstetrics, Gynecology and Reproductive Medicine, Educational and Scientific Institute of Postgraduate Education

M. I. Pavliuchenko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Obstetrics and Gynecology

M. Yu. Serhiienko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Obstetrics and Gynecology

A. O. Kniazieva, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, Postgraduate Student at the Department of Obstetrics and Gynecology

References

  1. La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, Jet al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Prz Menopauzalny. 2019;18(2):116-22. doi: https://doi.org/10.5114/pm.2019.86836
  2. Cox S, Nasseri R, Rubin RS, Santiago-Lastra Y. Genitourinary Syndrome of Menopause. Med Clin North Am. 2023;107(2):357-69. doi: https://doi.org/10.1016/j.mcna.2022.10.017
  3. Shim S, Park KM, Chung YJ, Kim MR. Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements. J Menopausal Med. 2021;27(1):1-7. doi: https://doi.org/10.6118/jmm.20034
  4. Ilhan G, Aslan MM, Cevrioglu AS, Yıldırım M, Erkorkmaz U. Clinical Efficacy of Hormonal and Nonhormonal Agents in the Treatment of Vulvovaginal Atrophy. J Menopausal Med. 2021;27(1):15-23. doi: https://doi.org/10.6118/jmm.20026
  5. Popkov О.V. [Benefits of topical estrogen in the treatment of urogenital menopause syndrome]. Ukrainian medical journal. 2021;0(6):2-6. Ukrainian. doi: https://doi.org/10.32471/umj.1680-3051.146.223310
  6. Costa AP, Sarmento AC, Vieira-Baptista P, Eleutério J Jr, Cobucci RN, Gonçalves AK. Hormonal Approach for Postmenopausal Vulvovaginal Atrophy. Front Reprod Health. 2021;3:783247. doi: https://doi.org/10.3389/frph.2021.783247
  7. Pérez-López FR, Vieira-Baptista P, Phillips N, Cohen-Sacher B, Fialho SC, Stockdale CK. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecol Endocrinol. 2021;37(8):740-5. doi: https://doi.org/10.1080/09513590.2021.1931100
  8. Ojha N, Bista KD, Bajracharya S, Katuwal N. Genitourinary Syndrome of Menopause among Postmenopausal Women in a Tertiary Care Centre: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2022;60(246):126-31. doi: https://doi.org/10.31729/jnma.7237
  9. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44. doi: https://doi.org/10.3109/13697137.2011.647840
  10. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-9. doi: https://doi.org/10.1111/jsm.12190
  11. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. J Sex Med. 2017;14(3):413-24. doi: https://doi.org/10.1016/j.jsxm.2017.01.010
  12. Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704-11. doi: 1 https://doi.org/0.1016/j.ajog.2016.07.045
  13. Lev-Sagie A. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. Clin Obstet Gynecol. 2015;58(3):476-91. doi: https://doi.org/10.1097/GRF.0000000000000126
  14. Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. Clin Breast Cancer. 2015;15(6):413-20. doi: https://doi.org/10.1016/j.clbc.2015.06.005
  15. Nappi RE, Biglia N, Cagnacci A, Di Carlo C, Luisi S, Paoletti AM. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol. 2016;32(8):602-6. doi: https://doi.org/10.1080/09513590.2016.1183627
  16. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. doi: https://doi.org/10.1097/GME.0000000000001609
  17. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 Pt 1):355-71. doi: https://doi.org/10.1097/gme.0b013e31805170eb
  18. Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23(5):514-22. doi: https://doi.org/10.1111/j.1529-8019.2010.01354.x
  19. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol. 2004;190(5):1272-7. doi: https://doi.org/10.1016/j.ajog.2003.12.015
  20. Stabile G, Topouzova GA, De Seta F. The role of microbiota in the management of genitourinary syndrome of menopause. Climacteric. 2023;26(4):353-60. doi: https://doi.org/10.1080/13697137.2023.2223923
  21. Micks E, Reed SD, Mitchell C. The Postmenopausal Vaginal Microbiome and Genitourinary Syndrome of Menopause. Clin Obstet Gynecol. 2024;67(1):79-88. doi: https://doi.org/10.1097/GRF.0000000000000832
  22. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med. 2009;6(3):603-619. doi: https://doi.org/10.1111/j.1743-6109.2008.01198.x
  23. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-22. doi: https://doi.org/10.3109/13697137.2010.522875
  24. Palacios S, Combalia J, Emsellem C, Gaslain Y, Khorsandi D. Therapies for the management of genitourinary syndrome of menopause. Post Reprod Health. 2020;26(1):32-42. doi: https://doi.org/10.1177/2053369119866341
  25. Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sex Med Rev. 2018;6(4):558-71. doi: https://doi.org/10.1016/j.sxmr.2018.03.005
  26. Mension E, Alonso I, Tortajada M, Matas I, Gómez S, Ribera L, Ros C, Anglès-Acedo S, Castelo-Branco C. Genitourinary Syndrome of Menopause Assessment Tools. J Midlife Health. 2021;12(2):99-102. doi: https://doi.org/10.4103/jmh.jmh_93_21
  27. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. doi: https://doi.org/10.1080/009262300278597
  28. Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015;26(1):15-28. doi: https://doi.org/10.1007/s00192-014-2464-0
  29. McEndree B. Clinical application of the vaginal maturation index. Nurse Pract. 1999;24(9):48-56.
  30. O'Connell TX, Nathan LS, Satmary WA, Goldstein AT. Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77(3):321-6.
  31. Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014;21(5):450-8. doi: https://doi.org/10.1097/GME.0b013e3182a4690b
  32. Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321-30. doi: https://doi.org/10.1097/GME.0000000000001236
  33. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric. 2014;17(5):557-63. doi: https://doi.org/10.3109/13697137.2014.946279
  34. Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas. 2016;83:40-4. doi: https://doi.org/10.1016/j.maturitas.2015.09.001
  35. Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167-73. doi: https://doi.org/10.1080/13697137.2017.1421921
  36. Farahat RA, Salamah HM, Mahmoud A, Hamouda E, Hashemy M, Hamouda H, et al. The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis. BMC Womens Health. 2023;23(1):494. doi: https://doi.org/10.1186/s12905-023-02645-0
  37. Tersigni C, Di Simone N, Tempestilli E, Cianfrini F, Russo R, Moruzzi MC, et al. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women. J Obstet Gynaecol. 2015;35(8):835-8. doi: https://doi.org/10.3109/01443615.2015.1014326
  38. Hocké C, Diaz M, Bernard V, Frantz S, Lambert M, Mathieu C, et al. Syndrome génito-urinaire de la ménopause (SGUM). RPC les femmes ménopausées du CNGOF et du GEMVi [Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol. 2021;49(5):394-13. French. doi: https://doi.org/10.1016/j.gofs.2021.03.025
  39. Reed BD, Harlow SD, Legocki LJ, Helmuth ME, Haefner HK, Gillespie BW, et al. Oral contraceptive use and risk of vulvodynia: a population-based longitudinal study. BJOG. 2013;120(13):1678-84. doi: https://doi.org/10.1111/1471-0528.12407
  40. Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18 Suppl 1:18-22. doi: https://doi.org/10.3109/13697137.2015.1078206
  41. Sarmento AC, Kamilos MF, Costa AP, Vieira-Baptista P, Eleutério J Jr, Gonçalves AK. Use of Moisturizers and Lubricants for Vulvovaginal Atrophy. Front Reprod Health. 2021;3:781353. doi: https://doi.org/10.3389/frph.2021.781353
  42. Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women. Menopause. 2018;25(12):1418-23. doi: https://doi.org/10.1097/GME.0000000000001148
  43. Ministry of Health of Ukraine. [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Menopausal disorders and other disorders in the perimenopausal period"]. Order dated 2022 Jun 17, No. 1039. [Internet]. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/37474-dn_1039_17_06_2022_dod.pdf
  44. Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause. 2014;21(3):309-19. doi: https://doi.org/10.1097/GME.0b013e31829755ed
  45. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-53. doi: https://doi.org/10.1097/GME.0000000000000921
  46. Ministry of Health of Ukraine. [Evidence-Based Clinical Guidelines Menopausal Disorders and Other Perimenopausal Disorders] [Internet]. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/2022_01_13_kn_menopauz_rozlady.pdf
  47. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric. 2016;19(2):151-61. doi: https://doi.org/10.3109/13697137.2015.1124259
  48. Mills BB. Vaginitis: Beyond the Basics. Obstet Gynecol Clin North Am. 2017;44(2):159-77. doi: https://doi.org/10.1016/j.ogc.2017.02.010
  49. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. doi: https://doi.org/10.1097/gme.0b013e31824d8f40
  50. Heller DS, Weiss G, Bittman S, Goldsmith L. Does a diagnosis of atrophic vaginitis on Papanicolaou test signify the presence of inflammation?. Menopause. 2015;22(8):814-5. doi: https://doi.org/10.1097/GME.0000000000000393
  51. Nappi RE, Kotek M, Breštánský A, Giordan N, Beriotto I, Tramentozzi E. Treatment of vulvo-vaginal atrophy with hyaluronate-based gel: a randomized controlled study. Minerva Obstet Gynecol. 2022;74(6):480-8. doi: https://doi.org/10.23736/S2724-606X.21.04841-7
  52. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3-9. doi: https://doi.org/10.3109/13697137.2013.871696
  53. Kovacevic N, Cilensek I, Merlo S, Segedin B. Modern approach to the management of genitourinary syndrome in women with gynecological malignancies. Radiol Oncol. 2023;57(3):292-8. doi: https://doi.org/10.2478/raon-2023-0038
  54. Rioux JE, Devlin MC, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2018;25(11):1208-13. doi: https://doi.org/10.1097/GME.0000000000001220
  55. Motlani G, Motlani V, Acharya N, Dave A, Pamnani S, Somyani D, et al. Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift. Cureus. 2023;15(11):e49079. doi: https://doi.org/10.7759/cureus.49079
  56. Archer DF. Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy. Menopause. 2020;27(8):846-7. doi: https://doi.org/10.1097/GME.0000000000001600
  57. Leibaschoff G, Izasa PG, Cardona JL, Miklos JR, Moore RD. Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the Treatment of Menopausal Vaginal/Genitourinary Symptoms. Surg Technol Int. 2016;29:149-59.
  58. Lee A, Kim TH, Lee HH, Kim YS, Enkhbold T, Lee B, et al. Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials. J Menopausal Med. 2018;24(1):1-10. doi: https://doi.org/10.6118/jmm.2018.24.1.1
  59. Kwon TR, Kim JH, Seok J, Kim JM, Bak DH, Choi MJ, et al. Fractional CO2 laser treatment for vaginal laxity: A preclinical study. Lasers Surg Med. 2018 Sep;50(9):940-947. doi: https://doi.org/10.1002/lsm.22940
  60. Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Falagas ME, Salvatore S, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause. 2019;26(3):248-55. doi: https://doi.org/10.1097/GME.0000000000001206
  61. Fan W, Tang J, Tang S, Lin Z, Li M, Zhang Z, Wu D. Bibliometric analysis of photodynamic therapy and immune response from 1989-2023. Front Pharmacol. 2024 Jan 15;15:1299253. doi: https://doi.org/10.3389/fphar.2024.1299253
  62. Sun J, Zhao H, Fu L, Cui J, Yang Y. Global Trends and Research Progress of Photodynamic Therapy in Skin Cancer: A Bibliometric Analysis and Literature Review. Clin Cosmet Investig Dermatol. 2023;16:479-98. doi: https://doi.org/10.2147/CCID.S401206
  63. Huang F, Fu Q, Tang L, Zhao M, Huang M, Zhou X. Trends in photodynamic therapy for dermatology in recent 20 years: A scientometric review based on CiteSpace. J Cosmet Dermatol. 2024;23(2):391-402. doi: https://doi.org/10.1111/jocd.16033
  64. Qiu L, Li J, Chen F, Wang Y, Wang Y, Wang X, et al. Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). Photodiagnosis Photodyn Ther. 2022;39:102993. doi: https://doi.org/10.1016/j.pdpdt.2022.102993
  65. Lan T, Zou Y, Hamblin MR, Yin R. 5-Aminolevulinic acid photodynamic therapy in refractory vulvar lichen sclerosus et atrophicus: Series of ten cases. Photodiagnosis Photodyn Ther. 2018;21:234-8. doi: https://doi.org/10.1016/j.pdpdt.2017.12.003
  66. Ou S, Wang H, Liu W, Zhu H, Zhang W, Li H, et al. Combination of high-frequency electrocautery therapy and ALA-PDT in hyperkeratotic vulvar lichen sclerosus: Series of seven cases. Photodiagnosis Photodyn Ther. 2024;45:103924. doi: https://doi.org/10.1016/j.pdpdt.2023.103924
  67. Singh N, Mishra N, Ghatage P. Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review. Cureus. 2021;13(2):e13527. doi: https://doi.org/10.7759/cureus.13527
  68. Corazza M, Schettini N, Zedde P, Borghi A. Vulvar Lichen Sclerosus from Pathophysiology to Therapeutic Approaches: Evidence and Prospects. Biomedicines. 2021;9(8):950. doi: https://doi.org/10.3390/biomedicines9080950

Downloads

Additional Files

Published

2024-12-04

How to Cite

1.
Siusiuka VH, Avramenko NV, Pavliuchenko MI, Serhiienko MY, Kniazieva AO. Vulvovaginal atrophy: modern approaches to diagnostics and management. Zaporozhye Medical Journal [Internet]. 2024Dec.4 [cited 2026May21];26(6):506-11. Available from: https://zmj.zsmu.edu.ua/article/view/311942

Issue

Vol. 26 No. 6 (2024)

Section

Review

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons